Internal Medicine, Hematology & Oncology · Norwich, CT
NPI
1386719060
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
2
Medicare group memberships
Hospitals
4
Hospital affiliations
330 Washington St Ste 220
Norwich, CT, 06360
Phone (860) 886-8362
Groups this clinician bills Medicare through
Medicare paid, 2024
$2.1M
130,215 services
Medicare patients, 2024
650
Average age 74
Drug cost, 2024
$5.3M
2,224 prescriptions
Company payments, 2025
$3,542
From 43 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Jie Yang was code Q0138 (injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use)), 19,890 times for 25 patients. In total Jie Yang billed 130,215 services in 156 codes, and Medicare paid $2.1M.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2009-12-31.
| Code |
|---|
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| Q0138 Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 19,890 | 25 | $0.26 | $5,240 |
| J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 15,582 | 14 | $2.32 | $36K |
| J0897 Injection, denosumab, 1 mg | Office | 5,760 | 38 | $20.31 | $117K |
| J1569 Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | Office | 2,000 | 15 | $36.04 | $72K |
| 85025 Blood Count | Office | 1,317 | 402 | $7.57 | $9,965 |
| 36415 Venipuncture Blood Collection | Office | 1,190 | 401 | $8.58 | $10K |
| 99490 Chronic, Principal, and Transitional Care Management | Office | 1,186 | 137 | $52.10 | $62K |
| 80053 Clinical Chemistry | Office | 809 | 319 | $10.30 | $8,336 |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 728 | 18 | $0.09 | $65.98 |
| 99214 Office E&M - Established | Office | 681 | 376 | $99.94 | $68K |
| 83615 Clinical Chemistry | Office | 621 | 265 | $5.91 | $3,672 |
| 96372 Injection Administration | Office | 390 | 92 | $11.88 | $4,633 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 322 | 186 | $13.99 | $4,506 |
| 82728 Clinical Chemistry | Office | 241 | 145 | $13.30 | $3,206 |
| 99215 Office E&M - Established | Office | 228 | 111 | $148.16 | $34K |
By year: 2022 $1.7M for 97,744 services; 2023 $1.9M for 105,846 services; 2024 $2.1M for 130,215 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 1,317 | 402 | $7.57 | $9,965 |
| 36415 Venipuncture Blood Collection | 1,190 | 401 | $8.58 | $10K |
| 80053 Clinical Chemistry | 809 | 319 | $10.30 | $8,336 |
| 83615 Clinical Chemistry | 621 | 265 | $5.91 | $3,672 |
| 82728 Clinical Chemistry | 241 | 145 | $13.30 | $3,206 |
| 83540 Clinical Chemistry | 211 | 137 | $6.31 | $1,331 |
| 83550 Clinical Chemistry | 210 | 137 | $8.53 | $1,791 |
| 82784 Immunoassay | 180 | 32 | $9.11 | $1,640 |
| 82607 Clinical Chemistry | 136 | 91 | $14.78 | $2,010 |
| 82746 Clinical Chemistry | 103 | 75 | $14.41 | $1,484 |
Medicare prescription drug claims, 2024
In 2024, the drug Jie Yang prescribed most often to Medicare patients was Eliquis (Apixaban), with 231 prescriptions and refills. In total Jie Yang wrote 2,224 Medicare prescriptions that cost $5.3M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Eliquis Apixaban | 231 | 348 | 45 | $203K |
| Anastrozole Generic | 199 | 567 | 68 | $3,490 |
| Letrozole Generic | 121 | 294 | 33 | $3,331 |
| Gabapentin Generic | 77 | 124 | 21 | $1,229 |
| Xarelto Rivaroxaban | 67 | 159 | 21 | $88K |
| Omeprazole Generic | 62 | 112 | 19 | $774 |
| Oxycodone Hcl Generic | 57 | 57 | 14 | $963 |
| Exemestane Generic | 57 | 155 | 16 | $3,933 |
| Revlimid Lenalidomide | 52 | 52 | Under 11 | $1.0M |
| Ondansetron Odt Ondansetron | 52 | 52 | 31 | $478 |
| Hydroxyurea Generic | 48 | 118 | 12 | $787 |
| Levofloxacin Generic | 47 | 47 | 18 | $153 |
| Prednisone Generic | 45 | 53 | 14 | $203 |
| Alendronate Sodium Generic | 43 | 109 | 13 | $258 |
| Abiraterone Acetate Generic | 42 | 42 | Under 11 | $31K |
Brand drugs: 615 claims; generic drugs: 1,609 claims; opioid claims: 130.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Jie Yang $3,542 ($3,542 in general payments such as food, travel and fees) from 43 companies. The largest payer was AstraZeneca Pharmaceuticals LP with $314.
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP AZN | 14 | $314 |
| Novartis Pharmaceuticals Corporation NVS | 13 | $299 |
| Pfizer Inc. PFE | 14 | $261 |
| Rigel Pharmaceuticals, Inc. RIGL | 8 | $211 |
| Janssen Biotech, Inc. JNJ | 10 | $196 |
| Gilead Sciences, Inc. GILD | 6 | $140 |
| Eisai Inc. 4523.T | 6 | $137 |
| Merck Sharp & Dohme LLC MRK | 6 | $134 |
| Abbvie Inc. ABBV | 5 | $114 |
| Exelixis Inc. EXEL | 5 | $111 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.